

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	:	Examiner: Laura Lynne Stockton
TAKAO NAKAJIMA, ET AL.	)	
	:	Group Art Unit: 1626
Application No.: 10/584,633	)	
	:	Confirmation No. 5585
Filed: June 26, 2006	)	
	:	
U.S. Patent No. 7,718,808	)	
	:	
Issue Date: May 18, 2010	)	
	:	November 9, 2011
For: THIAZOLE DERIVATIVES	:	

Attention: Mary Diggs, Supervisor  
Decisions & Certificates of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR RECONSIDERATION

Sir:

This is in response to the U.S. Patent and Trademark Office Communication re Request for Certificate of Correction dated August 24, 2011 in the above-identified patent.

The Communication denied correction of the specific errors noted therein. This decision is not at all well-understood, nor is in conformity with Title 35, the USPTO Rules of Practice or MPEP §1400, as discussed below in detail.

That is, as to the changes themselves, *each* simply concerns a mere punctuation or spelling error, as noted below.

Correction

Comment

COLUMN 192

Line 50, "of" should be deleted

Delete "of"

COLUMN 198

Line 61, "Compound 115" should read  
--Compound 116--

Change "115" to --116--

COLUMN 199

Line 48, "<sup>1</sup>H NMR (CDCl<sub>3</sub>, ppm):" should read  
--<sup>1</sup>H NMR (CDCl<sub>3</sub>, δ ppm):--

Add " δ"

COLUMN 216

Line 7, "Compound 166" should read  
--Compound 171--

Change "166" to --171--

COLUMN 218

Line 41, "(155'mg," should read --155 mg--

Delete " ' "

COLUMN 226

Line 11, "(31.1 mg," should read --(311 mg,--

Change "31.1" to --311--

COLUMN 244

Line 10, "6.65 (dd, j=1.6, 3.5Hz,—1H)," should read  
--6.65 (dd, J=1.6, 3.5Hz, 1H),--

Change "—" to --,--

COLUMN 269

Line 61, "crude." should read --crude--

Delete "."

COLUMN 273

Line 51, "8.75 (br s, 2H)" should read --8.75 (br s, 2H).--

Add --,--

COLUMN 287

Line 9, "N-[5-(Cyclopentylcarbonyl)-4-(2-furyl)thiazol-2-]"  
should read  
--N-[5-(Cyclopentylcarbonyl)-4-(2-furyl)thiazol-2- --

Change  
"Cyclopentylcarbonyl" to  
--Cyclopentylcarbonyl--

COLUMN 290

Line 19, "Compound" (first occurrence) should read  
--Compound 443--

Add --443--

CorrectionCommentCOLUMN 300

Line 59, "(111 mg, 53)" should read --111 mg, 53%)--

Add --%--

COLUMN 324

Line 63, "J=11.9," should read --J=1.9,--

Change "11.9" to --1.9--

COLUMN 325

Line 10, "(122 mg;" should read --(122 mg,--

Change ";" to --,--

COLUMN 327

Line 38, "7.7%)." should read --77%).--

Change "7.7" to --77--

COLUMN 329

Line 7, "2-methoxy-2-methylpropylpiperazine" should read  
--1-(2-methoxy-2-methylpropyl)piperazine--

Change  
"methylpropylpiperazine" to  
--methylpropyl)piperazine--

COLUMN 330

Line 7, "added" should read --was added--

Add --was--

COLUMN 332

Line 15, "9.00 mmol)" should read --0.900 mmol)--;  
Line 36, "9.00 mmol)" should read --0.900 mmol)--; and  
Line 56, "9.00 mmol)" should read --0.900 mmol)--

Change "9.00" to --0.900--  
Change "9.00" to --0.900--  
Change "9.00" to --0.900--

COLUMN 333

Line 8, "9.00 mmol)" should read --0.900 mmol)--; and  
Line 26, "9.00 mmol)" should read --0.900 mmol)--

Change "9.00" to --0.900--;  
Change "9.00" to --0.900--

COLUMN 351

Line 4, "sulfate;" should read --sulfate,--

Change ";" to --,--

COLUMN 352

Line 43, "8.dd" should read --8.33--

Change "dd" to --33--

As discussed above, since none of these changes is understood to be anything other than "a mistake of a clerical or typographical nature, or of minor character", each is in conformity with the Rules of Practice and is accordingly entitled to correction under 35 U.S.C. §255.

Therefore, if for any reason any of the foregoing corrections is again denied, the USPTO is respectfully requested to report its reasons for such denial in detail.

Entry hereof and correction of the above-identified patents as previously requested are earnestly solicited.

Patentees' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

/Lawrence S. Perry/  
Lawrence S. Perry  
Attorney for Patentees  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
Facsimile: (212) 218-2200

LSP/ac